Even though there was a decline at the start of the year, some areas of the market are still performing well.
Gilead Sciences, Inc. (NASDAQ:GILD) will participate in the Leerink Partners Global Healthcare Conference Call on March 11, 2025, at 10:40 AM ET. The company will be represented by Cindy Perettie, who is the Executive Vice President and Global Head of Kite. Daina Graybosch from Leerink Partners will also be part of the call and will kick things off.
Gilead Sciences and Johnson & Johnson are included in the Zacks Investment Ideas article.
This is a comparison of how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have done in relation to their industry during this year.
Gilead Sciences (GILD), a leader in the medical field, has reached new 52-week highs in its stock price, even as the overall market has experienced a significant decline in recent weeks.
Gilead (GILD) has reached its highest point in 52 weeks, but can investors expect further increases? We will examine the company's fundamentals for insights.
In this period of increased market fluctuations, it's beneficial to invest wisely.
Gilead Sciences, Inc. (NASDAQ:GILD) will be participating in the 45th Annual Healthcare Conference hosted by TD Cowen on March 4, 2025, at 11:10 AM ET. The company will be represented by Johanna Mercier, the Chief Commercial Officer. Tyler Van Buren, a Senior Biotech Analyst at TD Cowen, will also be part of the conference call.
In this period of increased market fluctuations, it's beneficial to invest wisely.
At the end of the last trading day, Gilead Sciences (GILD) was priced at $115.99, which represents a 1.47% increase compared to the previous day.